In breast cancer, the inhibition of TG2 can be used as a therapeutic strategy to overcome PD-L1 inhibitor resistance in PD-L1(+) TNBC patients since this reestablished T cell-dependent cytotoxicity by impeding the expression of both PD-L1 and CCL2 [38]. The gene discussed is CD274; the disease is breast carcinoma.